CCCC C4 Therapeutics

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

C4T to Host Webcast on September 20, 2025 at 3 pm ET

WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025 at 11:10 am ET in Toronto, Canada.

IMS Annual Meeting 2025 Oral Presentation

Title: Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Presentation Date and Time: Saturday, September 20, 2025 at 11:10 am ET

Session: Future Targets and New Modalities of Therapy

Location: Metro Toronto Convention Centre - South Building, Room 701

Presenter: Binod Dhakal, M.D., M.S., associate professor of medicine, Medical College of Wisconsin, Division of Hematology

C4T has completed enrollment and dose escalation for its Phase 1 trial of cemsidomide in MM, which continues to demonstrate a well-tolerated safety profile and compelling response rates. The presentation at the IMS Annual Meeting will include data from all safety and efficacy evaluable MM patients from all dose levels studied in the cemsidomide with dexamethasone cohort in the Phase 1 trial. C4T’s investor webcast will highlight the data from the oral presentation at the IMS Annual Meeting and provide additional detail on the company’s planned next steps of clinical development.

C4T Investor Webcast

C4T will host a webcast on September 20, 2025 at 3 pm ET. To join the webcast, please visit this  or the “Events & Presentations” page of the Investors section on the company’s website at . A replay of the webcast will be archived and available following the event. Additionally, following the oral presentation at the IMS Annual Meeting, C4T will share that presentation on its website under the .

About C4 Therapeutics

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit .

About Cemsidomide

Cemsidomide is an investigational, orally bioavailable small-molecule degrader designed to be a more potent and selective degrader of IKZF1/3, transcription factors that drive multiple myeloma (MM) and non-Hodgkin’s lymphomas (NHL), with unique pharmacokinetic properties. Clinical data has shown that cemsidomide is well-tolerated. In MM, cemsidomide displays compelling evidence of anti-myeloma activity and immunomodulatory effects. More information may be accessed at  (identifier: NCT04756726).

Contacts:

Investors:

Courtney Solberg

Associate Director, Investor Relations

Media:

Loraine Spreen

Senior Director, Corporate Communications & Patient Advocacy



EN
03/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on C4 Therapeutics

 PRESS RELEASE

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA). BIIB142 is a degrader of IRAK4 that Biogen intends to explore for therapeuti...

 PRESS RELEASE

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide ...

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting C4T to Host Webcast on September 20, 2025 at 3 pm ET WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (...

 PRESS RELEASE

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Rece...

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level Productive Type C Meeting Held With FDA; Registrational Development of Cemsidomide in Multiple Myeloma on Track to Initiate in Early 2026 Preclinical Milestone Achieved Under the Collaboration With Merck KGaA, Darmstadt, Germany, Which ...

 PRESS RELEASE

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recen...

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease Negative Complete Response; 40% ORR Achieved at the 75 µg Dose Level Cemsidomide Multiple Myeloma Dose Escalation is Complete; FDA Feedback Expected by Mid-Year 2025 to Support Initiation of Next Phase of Development in Early 2026 ...

 PRESS RELEASE

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Re...

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million as of December 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Feb. 27, 2025 (GLOBE N...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch